New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma

/ Print /
| ShareMore
/ Text Size +
12/10/21 3:00 pm EDT
Hyatt Regency Atlanta + Live Streaming

The treatment landscape for patients with multiple myeloma (MM) has evolved rapidly in recent years due to an enhanced understanding of the heterogeneous nature of the disease. As novel therapies start to be incorporated in the frontline and relapsed settings, clinicians are frequently unsure of how to appropriately choose therapies to improve patient outcomes.

Learning Objectives

The learning objectives of this program are:

  • Translate patient-specific factors, risk stratification, and treatment history into personalized treatment plans for patients with R/R MM
  • Assess recent results from pivotal trials on current and emerging therapeutic approaches for the treatment of R/R MM
  • Implement effective strategies to monitor and mitigate the negative impact of treatment-related toxicities in patients with R/R MM
  • Apply recent guidelines in parallel with practice-changing evidence on evolving single agent and combination approaches to real-world case scenarios typically encountered in R/R MM management

Target Audience

The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate.


December 10, 2021

Registration and Lunch: 2:15 PM – 3:00 PM EST

Scientific Session: 3:00 PM- 5:00 PM EST